

Modeling Obesity, Diabetes, and GLP-1 Receptor Agonists

Eli Bullock-Papa
Virginia Tech

Abstract

The rising prevalence of obesity and Type 2 Diabetes (T2D) represents a major public health challenge, with adult obesity rates in the United States reaching 41.9

Our model successfully captured long-term weight loss trajectories and inflammation reduction patterns observed in clinical trials. However, significant discrepancies emerged in acute metabolic responses, particularly in glucose and insulin dynamics. The model consistently overestimated these parameters, suggesting limitations in its representation of early treatment effects. Most notably, for severely obese patients ($\text{BMI} \geq 40$), the model predicted persistent metabolic dysfunction that contradicts clinical evidence of successful treatment outcomes with GLP-1 agonists.

These findings highlight a crucial limitation: traditional model's reliance on caloric restriction as the sole mechanism of weight loss fails to capture the multiple pathways through which GLP-1 agonists improve metabolic health. Future refinements should incorporate direct effects on insulin sensitivity, beta cell preservation, and inflammation reduction beyond weight loss effects. Despite these limitations, this work provides valuable insights into the interconnected pathways of obesity and T2D, while establishing a framework for evaluating emerging therapeutic strategies beyond simple caloric modification.

Contents

1	Introduction	1	5	Conclusions	12
1.1	Modeling Objectives	2	5.1	Key Findings	12
2	Understanding Obesity and T2D	2	5.2	Model Limitations	12
2.1	Historical Perspective	2	5.3	Future Directions	13
2.2	Modern Understanding	2	5.4	Clinical Implications	13
2.3	Pathway Integration	3			
3	Setting up the simulation	5			
3.1	Data Measured in Trials	5			
3.2	Adjusting for our Model	6			
3.3	Binary Search for Caloric Requirements	6			
3.4	Model Parameter Adjustments	7			
3.5	Creating the Ramp-Up Function	8			
4	Model Results	9			
4.1	Recreating the STEP Trial	9			
4.2	Recreating the STASIS Trial	10			

1 Introduction

Obesity has become a pressing global health challenge, with alarming increases in both adult and childhood populations. In the United States alone, adult obesity rates have risen dramatically from 30.5% in 1999-2000 to 41.9% by 2020, affecting over 100 million adults. Even more concerning is the doubling of severe obesity rates from 4.7% to 9.2% during the same period. This epidemic extends to the younger generation, with approximately 20% of children and adolescents now classified

as obese^[1;2].

This widespread metabolic disorder is a significant risk factor for Type II Diabetes (T2D), driven by a complex interplay of insulin resistance, beta-cell dysfunction, and systemic inflammation. These metabolic disturbances result in chronic hyperglycemia, which is associated with severe complications, including cardiovascular disease and neuropathy.

GLP-1 receptor agonists, particularly Semaglutide, have emerged as revolutionary treatments in obesity and T2D management. These medications have demonstrated unprecedented efficacy in clinical trials, enabling significant and sustained weight loss while simultaneously improving glycemic control. The SELECT and STEP trials have validated their effectiveness, with long-term studies showing sustained benefits over two to five years^[3;4]. The complete mechanism of action extends beyond the well-understood effects of appetite suppression and delayed gastric emptying.

1.1 Modeling Objectives

The computational model central to this study was developed prior to the advent of GLP-1 agonists and focuses exclusively on simulating the effects of caloric intake modifications. Our approach involves replicating the observed weight loss patterns from clinical trials by modeling equivalent caloric restrictions. This methodology allows us to examine whether other metabolic parameters—such as glucose and free fatty acid (FFA) levels—align with clinical observations.

This validation process serves two crucial purposes. First, it establishes a baseline understanding of how caloric reduction alone influences the metabolic variables associated with obesity-induced T2D. Second, it provides a framework for evaluating the additional metabolic benefits specific to GLP-1 agonists that cannot be explained by reduced caloric intake alone. By identifying discrepancies between model predictions and clinical outcomes, we can highlight areas requiring refinement, ultimately enhancing the model's clinical relevance for current obesity and T2D therapeutic strategies.

2 Understanding Obesity and T2D

Historical perspective and modern understanding of obesity and diabetes pathways

2.1 Historical Perspective

The understanding of obesity and Type 2 Diabetes (T2D) has evolved significantly over the past century. Early theories centered primarily on insulin resistance and beta-cell dysfunction as independent phenomena. Researchers initially viewed obesity as a simple imbalance between caloric intake and energy expenditure, while T2D was considered primarily a disorder of insulin production.

This simplified view, while providing a foundation for early treatments, failed to capture

the complex interplay between adipose tissue, systemic inflammation, and metabolic regulation. The discovery of insulin in 1921 by Banting and Best marked a pivotal moment, but the intricate relationship between obesity and diabetes remained poorly understood for decades.

2.2 Modern Understanding

Current research reveals a more nuanced and interconnected pathway between obesity and T2D development. This process typically fol-

High insulin levels increase hepatic insulin sensitivity, reducing the liver's glucose output. In the equation, $HGP = HGP_{\text{bas}} + \frac{\text{hepa_max} \cdot (a_{\text{hgp}} + k_{\text{gcg}} \cdot g_{\text{cg}})}{(a_{\text{hgp}} + k_{\text{gcg}} \cdot g_{\text{cg}}) + \text{hepa_si} \cdot i}$, larger i (insulin) in the denominator lowers HGP.

2. Insulin to Glucose: (Insulin \uparrow) \rightarrow (Peripheral Glucose Clearance \uparrow)

Insulin enhances glucose uptake in peripheral tissues, increasing clearance. In the glucose balance, $dg = \text{gclamp} + HGP - (eg0 + sci \cdot si \cdot i)g$, a higher i strengthens the removal term ($sci \cdot si \cdot i$) g .

3. Insulin to FFA: (Insulin \uparrow) \rightarrow (FFA Release \downarrow)

Insulin suppresses lipolysis, reducing FFA release. The term $\frac{k_{\text{si}} f^{aa}}{k_{\text{si}} f^{aa} + (si \cdot f \cdot i)^{aa}}$ decreases as i rises, cutting back on FFAs liberated into circulation.

4. Liver to Glucose: (Liver \rightarrow Endogenous Glucose Production)

The liver contributes to blood glucose through HGP . This endogenous production term, HGP , adds to the glucose pool, influencing overall blood glucose levels.

5. Glucose to β -cell Mass: (Glucose homeostasis \uparrow or \downarrow) \rightarrow (β -cell Mass dynamics)

β -cell mass adjusts in response to glucose-driven signals for proliferation (p) and apoptosis (a). The metabolic rate m , derived from glucose g , influences p and a , thus determining whether β -cell mass grows or declines.

6. Glucose to EG0: (Constant Uptake \rightarrow Baseline Glucose Clearance)

Tissues like the brain remove glucose independently of insulin, modeled as $eg0$. This constant term ensures a baseline glucose uptake even in low-insulin states.

7. Glucose to β -cell Function: (Glucose \uparrow) \rightarrow (β -cell Function \uparrow , then possibly \downarrow with chronic excess)

Normal glucose enhances β -cell function and insulin secretion. Prolonged hyperglycemia, captured by terms like s_{glucu} and s_{glucd} , eventually impairs function if maintained at excessive levels.

8. β -cell Function to β -cell Mass: (Function \uparrow) \rightarrow (Mass Maintenance/Growth)

Higher β -cell function boosts insulin secretion and stimulates proliferation, increasing β -cell mass. Conversely, dysfunctional β -cells fail to support mass, leading to a net decline.

9. β -cell to Insulin: (β -cell Activity \uparrow) \rightarrow (Insulin Secretion \uparrow)

The β -cells produce insulin, with secretion rate isr depending on β -cell function and glucose signals. This links cell health directly to circulating insulin levels.

10. FFA to β -cell Function: (FFA \uparrow) \rightarrow (β -cell Function \downarrow)

Elevated FFAs impair β -cell function (lipotoxicity). The term s_{ffa} increases with FFA, reducing net β -cell functional capacity.

11. FFA to Insulin Sensitivity (Si): (FFA \uparrow) \rightarrow (Si \downarrow)

High FFAs contribute to insulin resistance by lowering Si . The model's $(1 - m_{\text{ffa}} \cdot \frac{f_{\text{ffa}}^{n_{\text{si}} - f_{\text{ffa}}}}{f_{\text{ffa}}^{n_{\text{si}} - f_{\text{ffa}}} + k_{\text{si}} - f_{\text{ffa}}^{n_{\text{si}} - f_{\text{ffa}}}})$ term shrinks as FFA grows, diminishing Si .

12. Fat Mass to FFA: (Fat Mass \uparrow) \rightarrow (FFA Release \uparrow)

Larger adipose stores boost lipolysis and FFA release. The $dffa$ equation includes $(cl0 + cl2 \cdot f_{\text{mass}})$, which increases as fat mass grows, raising FFA output.

13. Insulin Sensitivity (Si) to FFA Release: (Si \uparrow) \rightarrow (FFA Release \downarrow)

Improved insulin sensitivity makes insulin more effective at inhibiting FFA release. With higher Si , the term $(ksif^{aa}/(ksif^{aa} + (siff \cdot i)^{aa}))$ declines faster as i rises, reducing FFAs.

14. Fat Mass to Inflammation: (Fat Mass \uparrow) \rightarrow (Inflammation \uparrow)

Excessive adiposity elevates BMI, driving inflammation. The model's $dinfl$ includes a fraction $\frac{bmi^n_{infl}}{bmi^n_{infl} + k_{infl}^n_{infl}}$, which rises with BMI, increasing systemic inflammation.

15. Inflammation to Insulin Sensitivity (Si): (Inflammation \uparrow) \rightarrow (Si \downarrow)

Chronic inflammation impairs insulin signaling. In tsi , the factor $(\frac{ksi_{infl}}{ksi_{infl} + infl})$ diminishes as $infl$ grows, thereby reducing Si .

16. Inflammation to β -cell Function: (Inflammation \uparrow) \rightarrow (β -cell Function \downarrow)

Inflammatory cytokines damage β -cells and hinder insulin production. The term s_{infl} increases with inflammation, reducing net β -cell function (σ).

3 Setting up the simulation

Processing SELECT and STASIS trial data, and fitting unknown parameters to our model

3.1 Data Measured in Trials

To accurately model weight loss across different BMI categories, we analyzed data from both the SELECT and STASIS trials^[4]. Our goal was to determine the true treatment effect of semaglutide assuming perfect adherence.

Parameter	SELECT Trial	STASIS Trial	Units
Duration	4 years	2 years	years
Baseline Weight	105.6	BMI dependent	kg
Baseline Glucose	95.4	BMI dependent	mg/dl
Baseline Insulin	12.6	BMI dependent	μ U/ml
Height	1.65	1.8	m
Age	47.3	30	years

Table 1: Key measurements from both trials at baseline

For the SELECT trial, we incorporated three key components:

- Estimated Treatment Differences (ETD) for each BMI category
- Placebo group weight loss (-1.5% at 4 years)
- Adherence adjustment (+1.5% based on first on-treatment analysis)

The adherence-adjusted weight loss was calculated using:

$$\text{Adjusted Weight Loss} = (\text{ETD} + \text{Placebo Loss}) + 1.5\% \quad (1)$$

For the STASIS trial, baseline measurements varied by BMI category:

BMI Group	ETD (%)	Placebo (%)	Initial (%)	Adjusted (%)
BMI <30	-7.52	-1.5	-9.02	-10.52
BMI 30-35	-8.79	-1.5	-10.29	-11.79
BMI 35-40	-9.01	-1.5	-10.51	-12.01
BMI \geq 40	-9.23	-1.5	-10.73	-12.23

Table 2: SELECT trial weight loss percentages by BMI category, adjusted for adherence

Parameter	BMI <30	BMI 30-35	BMI 35-40	BMI \geq 40
Glucose (mg/dl)	96.21	102.73	112.93	122.40
Insulin (μ U/ml)	10.43	12.75	15.19	15.60
FFA (μ mol/l)	424.02	481.58	565.77	642.29
Inflammation	0.11	0.22	0.40	0.57

Table 3: STASIS trial baseline measurements by BMI category

3.2 Adjusting for our Model

To translate these findings into our simulation framework, we first converted BMI categories to target weights using our model subject’s height (1.8m). We then performed a binary search to determine both the pre-treatment caloric intake needed to reach each BMI category and the treatment-phase intake required to achieve the observed weight loss.

This process yielded the following caloric requirements:

BMI Group	Initial Weight (kg)	Initial Calories	Final Weight (kg)	Final Calories	Weight Change (%)
BMI <30	76.2	2,353	68.2	2,098	-10.5
BMI 30-35	88.5	2,730	78.0	2,401	-11.8
BMI 35-40	102.1	3,152	89.8	2,766	-12.0
BMI \geq 40	114.3	3,530	100.4	3,091	-12.2

Table 4: SELECT Trial Analysis Results (Pre-treatment: 7 years, Treatment: 4 years)

When we simulate the model with these caloric requirements, we get the following weight trajectories:

This matched the observed weight loss in the SELECT trial, indicating that our caloric requirements were accurate.

3.3 Binary Search for Caloric Requirements

To determine the caloric requirements for each phase of the trials, we implemented a binary search algorithm that finds the daily caloric intake needed to maintain a target weight. The algorithm:

1. Sets an initial range of possible calories (1500-6000 kcal/day)
2. Simulates weight trajectory for the midpoint caloric value
3. Narrows the search range based on whether the final weight is above or below target




Figure 2: Simulated weight trajectories by BMI category showing pre-treatment weight gain and subsequent Wegovy treatment response

4. Continues until the difference between final and target weight is within 0.1 kg

This process yielded the following caloric requirements for the SELECT trial:

BMI Group	Initial Weight (kg)	Initial Calories	Final Weight (kg)	Final Calories
BMI <30	76.2	2,353	68.2	2,098
BMI 30-35	88.5	2,730	78.0	2,401
BMI 35-40	102.1	3,152	89.8	2,766
BMI ≥ 40	114.3	3,530	100.4	3,091

Table 5: Caloric requirements determined through binary search for SELECT trial phases

And for the STEP trial:

Initial BMI	Initial Weight (kg)	Initial Calories	Final Weight (kg)	Final Calories
38.6	105.1	3,245	88.2	2,634

Table 6: Caloric requirements determined through binary search for STEP trial phases

3.4 Model Parameter Adjustments

Several parameters in our model were not directly measured in the clinical trials. To address this, we adjusted these parameters to match the observed biomarker values after two weeks of treatment. The following tables show the default values and the adjusted values for both trials:

Parameter	Default	Post 2-Week	Units
Free Fatty Acids	400	688.65	$\mu\text{mol/l}$
Insulin Sensitivity	0.8	0.26	$\text{ml}/\mu\text{U}/\text{day}$
Beta Cell Mass	1009	1009	mg
Insulin Secretion	530	501.64	$\mu\text{U}/\text{mg}/\text{day}$
Inflammation	0.056	0.45	dimensionless

Table 7: Parameter adjustments for SELECT trial to match 2-week biomarkers

Parameter	Default	Post 2-Week	Units
Free Fatty Acids	400	688.65	$\mu\text{mol/l}$
Insulin Sensitivity	0.8	0.26	$\text{ml}/\mu\text{U}/\text{day}$
Beta Cell Mass	1009	1009	mg
Insulin Secretion	530	501.64	$\mu\text{U}/\text{mg}/\text{day}$
Inflammation	0.056	0.45	dimensionless

Table 8: Parameter adjustments for STEP trial to match 2-week biomarkers

These adjustments were essential for ensuring our model most accurately reflected the physiological changes observed in the clinical trials while maintaining consistency with known biological mechanisms.

3.5 Creating the Ramp-Up Function

To accurately model the gradual onset of Wegovy’s appetite-suppressing effects, we implemented a ramp-up function that simulates the typical clinical titration schedule. The function gradually increases the medication’s effect over time, which better reflects real-world patient experiences and helps avoid sudden caloric restrictions.

$$\text{Ramp Factor} = \min\left(\frac{t - t_{\text{start}}}{t_{\text{ramp}}}, 1\right) \quad (2)$$

where:

- $t_{\text{start}} = 1825$ days (5-year pre-treatment period)
- $t_{\text{ramp}} = 60$ days (2-month ramp-up duration)

The caloric adjustment is then applied using:

$$\text{Caloric Reduction} = \text{Target Reduction} \times \text{Ramp Factor} \quad (3)$$

This gradual approach ensures that:

- The treatment effect increases linearly over the first year
- The full effect is achieved only after complete titration
- The simulation better matches clinical observations of weight loss patterns

4 Model Results

Validating the Model Against Clinical Trials

4.1 Recreating the STEP Trial

To validate our model's ability to capture the physiological changes induced by semaglutide, we first attempted to recreate the results from the STEP trial. This trial provided detailed biomarker measurements at baseline, 2 weeks, and 2 years, allowing for comprehensive validation of our model's predictions.

The simulation began with a subject matching the trial's baseline characteristics (BMI = 38.79 kg/m², weight = 105.6 kg) and tracked nine key biomarkers over the 2-year treatment period. Through binary search optimization, we determined that the pre-treatment caloric intake was 3,258 kcal/day, which decreased to 2,678 kcal/day during treatment.




Figure 3: Temporal evolution of nine key biomarkers during semaglutide treatment in the STEP trial. Blue lines represent model simulations while red dots show measured clinical data.

Figure 3 shows the temporal evolution of these biomarkers, revealing several notable patterns and discrepancies:

- **Glucose Dynamics (Panel A):** The model predicted significantly higher glucose levels than measured, showing an immediate jump from 95.4 mg/dl to 121.0 mg/dl, despite the measured baseline being lower. This suggests our model may overestimate initial glucose responses to treatment.

- **Insulin Response (Panel B):** Similar to glucose, the model predicted higher insulin levels than observed, jumping from 12.6 $\mu\text{U}/\text{ml}$ to 16.3 $\mu\text{U}/\text{ml}$ at treatment initiation. This consistent overestimation suggests potential refinements needed in our insulin response parameters.
- **Free Fatty Acids (Panel C):** While our model predicted a substantial decrease in FFA levels (from 688.7 to 619.7 $\mu\text{mol}/\text{l}$), clinical measurements showed a slight 0.3% increase. This discrepancy warrants further investigation into our FFA metabolism assumptions.
- **Insulin Sensitivity (Panel D):** S_i showed gradual improvement from 0.26 to 0.31 $\text{ml}/\mu\text{U}/\text{day}$, though without clinical measurements for validation.
- **Beta Cell Mass (Panel E):** The model predicted an initial decline followed by partial recovery, stabilizing around 994.6 mg. While plausible, direct validation was not possible as beta cell mass cannot be measured in vivo.
- **Insulin Secretion (Panel F):** Predicted increase from 501.6 to 554.7 $\mu\text{U}/\text{mg}/\text{day}$ aligns with expected compensatory responses to treatment.
- **Inflammation (Panel G):** The model's predicted 46.7% reduction in inflammation (0.45 to 0.24) closely matched the observed 56.7% decrease, providing strong validation of our inflammation dynamics.
- **BMI (Panel H):** The model accurately captured the reduction from 38.79 to 32.94 kg/m^2 , matching clinical measurements at both baseline and endpoint.
- **Disposition Index (Panel I):** The steady improvement in DPI (reaching -0.32) suggests enhanced glucose homeostasis, though direct clinical validation was not available.

These results demonstrate both strengths and limitations of our model. While it accurately captures long-term weight loss and inflammation reduction, the acute metabolic responses (particularly glucose and insulin) may require refinement. The model's predictions for unmeasurable parameters (beta cell mass, insulin sensitivity) appear physiologically plausible but would benefit from indirect validation through additional biomarkers.

4.2 Recreating the STASIS Trial

Our stasis model simulated treatment outcomes across four BMI categories (<30 , 30-35, 35-40, and ≥ 40), with a 5-year disease progression period followed by treatment. While the STASIS trial only provided weight change validation data, our simulation offers hypothetical insights into broader metabolic dynamics, albeit with important limitations noted from our STEP trial validation.

Analysis by panel reveals distinct patterns across BMI groups:

- **Glucose Dynamics (Panel A):** While lower BMI groups (<40) maintained relatively stable glucose levels, the BMI ≥ 40 group showed concerning progression to severe hyperglycemia ($>160 \text{ mg}/\text{dl}$) that persisted through treatment. However, this prediction likely overestimates glucose dysfunction, as clinical evidence shows GLP-1 medications can effectively normalize glucose in higher BMI patients through mechanisms beyond caloric restriction.




Figure 4: Temporal evolution of biomarkers across BMI groups during simulated disease progression (0-5 years) and treatment (5-7.5 years).

- **Insulin and FFA Levels (Panels B, C):** The model shows divergent patterns between BMI groups, with particularly concerning drops in insulin for BMI ≥ 40 . Given our STEP validation results, these specific predictions should be interpreted with caution.
- **Insulin Sensitivity (Panel D):** All groups show gradual improvement during treatment, though the magnitude varies significantly by initial BMI. The BMI ≥ 40 group shows minimal recovery, suggesting a potential “point of no return” in our model that may not reflect clinical reality.
- **Beta Cell Mass (Panel E):** A striking feature is the dramatic beta cell mass deterioration in the BMI ≥ 40 group, contrasting with stable or increasing mass in lower BMI groups. This prediction appears overly pessimistic given clinical observations of metabolic recovery in high-BMI patients. However, it is plausible under the assumption that the patient is only doing calorie restriction and not semaglutide.
- **Insulin Secretion (Panel F):** The model suggests severely compromised insulin secretion in the highest BMI group, while other groups maintain relatively stable function. This stark difference likely overestimates the irreversibility of beta cell dysfunction.
- **Inflammation (Panel G):** All groups show improvement with treatment, though the magnitude of reduction correlates with initial BMI. This general pattern aligns with expected inflammatory responses to weight loss.
- **BMI Trajectories (Panel H):** The model captures differential weight loss patterns

across groups, with higher initial BMIs showing larger absolute reductions. This aspect aligns with clinical observations.

- **Disease Progression Index (Panel I):** While lower BMI groups show improvement (moving into negative DPI values), the BMI ≥ 40 group maintains positive values, suggesting persistent metabolic dysfunction. This binary distinction likely oversimplifies the continuous nature of metabolic recovery.

Model Limitations: A critical limitation of our model is its failure to capture the full therapeutic effects of GLP-1 medications beyond caloric restriction. This is particularly evident in the BMI ≥ 40 group, where our model suggests irreversible metabolic dysfunction that contradicts clinical evidence of successful treatment outcomes. The model appears to overestimate the permanence of beta cell damage and underestimate the capacity for metabolic recovery in severe obesity. Future iterations should incorporate additional GLP-1 mechanisms of action, including direct effects on insulin sensitivity and beta cell function.

5 Conclusions

This study aimed to validate our computational model's ability to simulate the metabolic effects of significant weight loss by comparing it against clinical data from the SELECT and STEP trials. Our findings reveal both the strengths and limitations of the current model, while highlighting important areas for future development.

5.1 Key Findings

Our model successfully captured several important aspects of obesity and T2D treatment:

- Accurate prediction of weight loss trajectories across different BMI categories
- Realistic simulation of inflammation reduction during treatment
- Plausible representation of the complex interplay between metabolic parameters

However, significant discrepancies emerged when comparing detailed biomarker predictions to clinical measurements:

- Consistent overestimation of glucose

and insulin responses

- Overly pessimistic predictions for severe obesity cases
- Failure to capture the full therapeutic benefits observed in clinical trials

5.2 Model Limitations

The primary limitation of our current model is its reliance on caloric restriction as the sole mechanism of weight loss. This simplification fails to account for the multiple pathways through which GLP-1 agonists improve metabolic health:

- Direct effects on insulin sensitivity
- Beta cell preservation and function enhancement
- Inflammation reduction beyond weight loss effects
- Changes in lipid metabolism and substrate utilization

5.3 Future Directions

To improve the model’s clinical relevance, several enhancements should be considered:

- Integration of GLP-1 specific mechanisms beyond appetite suppression
- Refinement of acute metabolic response parameters
- Addition of tissue-specific insulin sensitivity measures
- Incorporation of metabolic flexibility indicators

5.4 Clinical Implications

Despite its limitations, this model provides valuable insights into the complex pathways linking obesity and T2D. Understanding these connections is crucial for:

- Optimizing treatment strategies
- Identifying early intervention opportunities
- Predicting individual treatment responses
- Developing more effective therapeutic approaches

In conclusion, while our model successfully captures many aspects of obesity-induced metabolic dysfunction, significant opportunities exist for improvement. Future iterations should focus on incorporating the multiple mechanisms of action of modern anti-obesity medications and not just caloric restriction. This would likely lead to more accurate predictions of treatment outcomes across the full spectrum of obesity and T2D presentations.

References

- [1] Centers for Disease Control and Prevention. Adult obesity facts, 2024. Accessed: 2024.
- [2] Centers for Disease Control and Prevention. Childhood obesity facts, 2024. Accessed: 2024.
- [3] W. Timothy Garvey, Rachel L. Batterham, Meena Bhatta, Silvio Buscemi, Louise N. Christensen, Juan P. Frias, Esteban Jódar, Kristian Kandler, Georgia Rigas, Thomas A. Wadden, and Sean Wharton. Two-year effects of semaglutide in adults with overweight or obesity: the step 5 trial. *Nature Medicine*, October 2022.
- [4] D.H. Ryan, I. Lingvay, J. Deanfield, et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the select trial. *Nature Medicine*, 30:2049–2057, 2024.